| Literature DB >> 28679969 |
Masahiko Yasuda1, Tomoyuki Ogura2, Takayuki Goto3, Mika Yagoto1, Yoko Kamai1, Chie Shimomura3, Nobuhito Hayashimoto4, Yukito Kiyokawa3, Hideki Shinohara3, Riichi Takahashi2, Kenji Kawai1.
Abstract
Severely immunodeficient NOD/Shi-scid, IL-2Rγnull (NOG) mice provide an in vivo model for human cell/tissue transplantation studies. NOG mice were established by combining interleukin-2 receptor-γ chain knockout mice and NOD/Shi-scid mice. They exhibit a high incidence of thymic lymphomas and immunoglobulin (Ig) leakiness. In this study, we assessed the incidence of malignant lymphomas and the occurrence of leakiness in 2,184 non-experimental NOG retired breeder mice aged 16-40 weeks. We established that the total incidence of lymphomas was only 0.60% (13/2,184). Most lymphomas (10/13) occurred in female mice by the age of around 25 weeks. No mice developed Ig leakiness. All lymphomas were derived from the thymus, and consisted mainly of CD3-positive and CD45R-negative lymphoblastic-like cells. Therefore, based on the absence of Ig leakiness and a very low incidence of lymphomas, including thymic lymphomas, NOG mice may be useful in regeneration medicine for xenotransplantation of human embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, and in transplantation experiments involving tumor cells.Entities:
Keywords: NOG mouse; thymic lymphoma
Mesh:
Substances:
Year: 2017 PMID: 28679969 PMCID: PMC5682355 DOI: 10.1538/expanim.17-0034
Source DB: PubMed Journal: Exp Anim ISSN: 0007-5124
Protocol used for each primary antibody
| Antibody | Host | Clone | Dilution | Antigen retrieval | Sourced) |
|---|---|---|---|---|---|
| Cleaved caspase-3 (Asp175) | Rabbit | Polyclonal | 1:1,500 | ER2a) | Cell Signaling Technology |
| CD3 | Rabbit | SP7 | 1:50 | ER1b) | Nichirei |
| mCD45R (B220) | Rat | RA3-6B2 | 1:200 | ER1b) | Santa Cruz Biotechnology |
| Ki-67 | Rabbit | SP6 | 1:100 | ER2a) | Abcam |
| Keratin/Cytokeratin | Rabbit | Polyclonal | 1:1 | Proteasec) | Nichirei |
a)Treated with ER2 (EDTA-based pH9.0 epitope retrieval solution; Leica Biosystems K.K., Tokyo, Japan) for 20 min at 100°C. b)Treated with ER1 (Citrate-based pH6.0 epitope retrieval solution; Leica Biosystems) for 30 min at 100°C. c)Treated with Protease Solution (Prediluted; Nichirei Biosciences, Inc., Tokyo, Japan) for 5 min at room temperature. d)Sources: Cell Signaling Technology, Inc. (Danvers, MA, USA), Nichirei Biosciences, Inc., Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), Abcam plc (Cambridge, UK).
Occurrence and incidence of visibly enlarged thymuses in NOG mice
| Age range (weeks) | Males (%) | Females (%) |
|---|---|---|
| 16–20 | 0/331 (0.00) | 8/310 (2.58) |
| 21–25 | 2/179 (1.12) | 1/180 (0.56) |
| 26–30 | 1/191 (0.52) | 0/207 (0.00) |
| 31–40 | 0/342 (0.00) | 1/444 (0.23) |
| 16–40 | 3/1043 (0.29) | 10/1,141 (0.88) |
Results are given as the number of mice presenting thymic enlargement/number of examined mice.
Fig. 1.Gross appearance of an enlarged thymus from a female NOG mouse aged 16–20 weeks (A), compared with a that from a same-age normal female NOG mouse (B). A: The enlarged thymus (arrowhead) is seen to occupy most of the thoracic cavity with lung hepatization and pleural effusion. B: The normal thymus is very small and buried in periaortic adipose tissue (arrow). Bars: 1 cm.
Characterization of the NOG mice with an enlarged thymus
| Case | Age range | Sex | Clinical symptoms | Necropsy finding | Body weight | Thymus weight | Spleen weight |
|---|---|---|---|---|---|---|---|
| 1 | 16–20 | Female | Weakening and anemic response | Enlarged thymus | 21.2 | 148 | 16 |
| 2 | 16–20 | Female | Weakening and anemic response | Enlarged thymus and spleen | 21.3 | 105 | 102 |
| 3 | 16–20 | Female | Wasting | Enlarged thymus and spleen | 20.3 | 436 | 428 |
| 4 | 16–20 | Female | Weakening and anemic response | Enlarged thymus | 23.4 | 162 | 51 |
| 5 | 16–20 | Female | No change | Enlarged thymus | 22.7 | 41 | 55 |
| 6 | 16–20 | Female | Weakening and anemic response | Enlarged thymus and spleen | 21.4 | 184 | 204 |
| 7 | 16–20 | Female | Weakening and anemic response | Enlarged thymus | 21.5 | 529 | 79 |
| 8 | 16–20 | Female | Wasting | Enlarged thymus and spleen | 15.2 | 40 | 125 |
| 9 | 21–25 | Male | Wasting | Enlarged thymus and spleen | 19.6 | 173 | 208 |
| 10 | 21–25 | Male | Wasting | Enlarged thymus, spleen and intrathoracic lymph nodes | 22.0 | 240 | 111 |
| 11 | 21–25 | Female | Wasting | Enlarged thymus, spleen, and intrathoracic lymph nodes | 21.1 | 1,202 | 322 |
| 12 | 26–30 | Male | Anemic response | Enlarged thymus and spleen | 24.0 | 657 | 431 |
| 13 | 31–40 | Female | Wasting | Enlarged thymus and spleen | 19.6 | 454 | 120 |
Fig. 2.Histopathological and immunohistochemical analysis of an enlarged thymus from a female NOG mouse (Fig. 1) and a normal thymus from a normal female NOG mouse. The normal thymus shows severe hypoplasia and mostly cytokeratin (CK)-positive thymic epithelial cells. In the enlarged thymus, CK-negative neoplastic cells show invasion to the CK-positive thymic epithelial meshwork structure. Bars: 200 µm.
Fig. 4.Representative histopathological features of an enlarged spleen in a NOG mouse with an enlarged thymus (Figs. 2 and 3) compared with a normal spleen. Neither CD3- nor CD45R-positive lymphocytes are observed in the normal spleen with extramedullary hematopoiesis. In the enlarged spleen, as well as in the enlarged thymus, CD3-positive and CD45R-negative neoplastic lymphocytes infiltrate into the perivascular lymphoid sheath in the white pulp. Bars: 200 µm.
Fig. 3.Histopathological and immunohistochemical analysis of an enlarged thymus and a normal one. High magnification of Fig. 2. In the normal thymus, thymic epithelial cells appear negative for CD3 and CD45R. In the enlarged thymus, CD3-positive and CD45R-negative neoplastic cells show monomorphous proliferation. Bars: 20 µm.
Fig. 5.Photomicrograph of neoplastic cells invading the lungs, liver, and kidneys of a female NOG mice aged 21–25 weeks. CD3-positive neoplastic cells invade the perivascular regions and expand diffusely. Bars: 200 µm.
Characterization of non-lymphomatous tumors in NOG mice
| Case | Age range | Sex | Clinical | Necropsy finding | Diagnosis |
|---|---|---|---|---|---|
| 1 | 21–25 | Female | None | The right lower abdominal subcutaneous mass in the region of the mammary gland | Adenocarcinoma [ |
| 2 | 26–30 | Female | None | Enlargement of the left ovary | Teratoma, benign [ |
| 3 | 26–30 | Female | None | Nodular lesion in the right lower lobe of the lung | Carcinoma, bronchiolo-alveolar [ |
| 4 | 31–40 | Female | None | Retroperitoneal mass | Rabdomyosarcoma [ |
| 5 | 31–40 | Female | None | The left lower abdominal subcutaneous mass in the region of the mammary gland | Adenoma [ |